FIXX News and Press, Homology Medicines Inc. From 05/11/23

2023-05-11 17:20:20 ET Homology Medicines press release ( NASDAQ: FIXX ): Q1 GAAP EPS of -$0.50 beats by $0.04 . Revenue of $0.8M (flat Y/Y) misses by $0.21M . As of March 31, 2023, Homology had approximately $150.0 million in cash, cash equivalents and short-t...

- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and Potential for Re-Dosing with AAVHSCs, at Upcoming ASGCT Meeting - - Soli...

- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency - BEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, ...

2023-03-16 10:03:57 ET Gainers: Lipella Pharmaceuticals ( LIPO ) +48% . ThermoGenesis Holdings ( THMO ) +34% . Genelux ( GNLX ) +14% . Homology Medicines ( FIXX ) +10% . Biora Therapeutics ( BIOR ) +7% . Losers: Esperi...

BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company’s Phase 1 phe...

2023-03-09 17:55:07 ET Homology Medicines press release ( NASDAQ: FIXX ): Q4 GAAP EPS of -$0.60 misses by $0.07 . Revenue of $0.82M (+2.5% Y/Y) misses by $0.1M . For further details see: Homology Medicines GAAP EPS of -$0.60 misses by $0.07, revenue of $0...

- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening - - Initial Clinical Data from Gene Therapy Trial for Hunter Syndrome Anticipated in Second Half of 2023; Trial Recruiting in the U...

2023-03-09 08:37:13 ET Genetic medicines company, Homology Medicines ( NASDAQ: FIXX ) announced that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr. Jordan held the role of senior VP, Head of Clinical Development and Operations, at...

BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr. Jordan held the role of Senior Vice President, Head of Clinical Development...

BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Ann...